BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Mar 12 2010

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. (Nasdaq:BPAX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. 

The full report is available at: http://www.beaconequity.com/i/BPAX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity

BioSante Pharmaceuticals Inc. (BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery.

Message Board Search:  http://www.boardcentral.com/boards/BPAX

In the report, the analyst notes:

"BPAX incurred a net loss of approximately $6.4 million or ($0.21) per share for the quarter ended September 30, 2009, compared to a net loss of $6.6 million or ($0.24) per share for the same period in 2008. This decrease in net loss was due to BPAX's decision in April 2009 to delay screening of new subjects for its ongoing LibiGel^® (testosterone gel) phase III safety study, partially offset by the recognition of acquisition related costs of approximately $1.5 million related to the Company's merger with Cell Genesys Inc., which closed October 14, 2009. Screening of new subjects for the safety study has been reinitiated.

"BPAX yesterday announced that studies of its GVAX vaccine showed the vaccine to be effective in battling chronic myeloid leukemia (CML). The vaccine was tested on patients with CML who were not responding as hoped to the leading treatment Gleevec. The study was conducted at Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland."